Immunotherapy efficacy predicted by plasma exosomes in patients with advanced non-small cell lung cancer (NSCLC)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040854

Enrollment

Unknown

Registered

2020-12-12

Start date

2020-12-01

Completion date

Unknown

Last updated

2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Cohort 1:patients who intend to receive anti PD-1 (pembrolizumab) therapy combined with chemotherapy as the first-line treatment

Cohort 2:patients who are going to receive second-line anti-PD-1 monotherapy (nivolumab) for progression after platinum based dual drug chemotherapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Cohort 1: patients who intend to receive anti PD-1 (pembrolizumab) therapy combined with chemotherapy as the first-line treatment. Cohort 2: patients who are going to receive second-line anti-PD-1 monotherapy (nivolumab) for progression after platinum based dual drug chemotherapy.

Exclusion criteria

Exclusion criteria: Participants in the group need to exclude a history of pneumonia, autoimmune diseases and receive systemic immunosuppressive therapy.

Design outcomes

Primary

Measure	Time frame
PD-L1 expression of exosom;exosome miRNA;	—

Countries

China

Contacts

Public ContactJialei Wang, Si Sun

Fudan University Shanghai Cancer Center

luwangjialei@126.com+86 18017312369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026